Current Illinois CancerCare Clinical Trials

Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

Study Number: EAZ171

Study Summary:
This phase II trial studies how well docetaxel or paclitaxel work in reducing chemotherapy-induced peripheral neuropathy in African American patients with stages I-III breast cancer. Drugs used in chemotherapy, such as docetaxel and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving docetaxel or paclitaxel may work better than other methods in reducing chemotherapy-induced peripheral neuropathy in patients with breast cancer.

Status: Open

Study Coordinator(s)
  • Courtney, 309-243-3660 cbrown@illinoiscancercare.com
  • Kiana, 309-243-3623, kshawd@illinoiscancercare.com
  • Hannah S, 309-243-3603, hshearburn@illinoiscancercare.com

Study Link

« Search Again